Skip to main content

Table 4 Prognostic factors from series considering unselected populations and related survivals

From: Surgical treatment of liver metastases of gastric cancer: state of the art

Author year Number Timing MST (months) 1-, 3-, 5-year survival rates Prognostic factors
2008 [37] 58 Synchronous + metachronous Overall: 16 No hepatic resection: 29.4%; 0%; 0%  
Hepatic resection RFA: 75.3%; 31.7%; 20.8% Ro resection     
2009 [50] 72 Synchronous NA No hepatic resection: 36.4%; 0%; 0%  
Hepatic resection (HAIC): 80%; 60%; 60% H; P; R0 resection     
2009 [51] 73 Metachronous Overall: 7   
BST: 5      
Chemotherapy: 12      
Hepatic resection: 23 BST: 22%; 2%; 0%     
Chemotherapy: 45%; 6%; 0%      
Hepatic resection; 81%; 20%; 20% T; N; G of primary     
R0 resection      
2009 [52] 73 Synchronous    Stage of primary; H
Extrahepatic disease; treatment of mets      
2010 [49]   Synchronous + metachronous Overall: 16   
Hepatic resection: 31.2 No hepatic resection: 53.2%; 4.2%; 0%     
Hepatic resection: 82.3%; 46.4%; 37.1%